At-Home Prescription Drug Disposal System

目的：证明安全、即时、经济、生态和用户友好的系统的有效性，该系统能够在家中灭活和处置精神活性处方药。Giner公司提出开发一种小型化的电解混合氧化剂（MOX）系统，以安全地销毁固体、液体或贴片形式的精神药物。所提出的系统被设计为临时连接到标准家用水龙头，以消除对额外设备的需要，并实现比现有技术更大的尺寸、性能和安全优势。第一阶段将评估概念的总体可行性，重点是混合氧化物反应堆的设计，并确定要求，以确保选择使用率高的药物。第一阶段侧重于以下具体目标： 1.设计、制造和组装BDD/MOX系统组件。通过设计电极结构和组装必要的部件，专注于开发/制造紧凑型和功能性的电解MOX反应器单元。 2.表征关键工艺变量和参数。将确定和优化工艺变量和参数，以充分电生成混合氧化剂，从而筛选选定的药品。 3.证明系统在选定药物上的适当性能。将使用根据处方频率、治疗类别和化学结构范围选择的精神活性药物（Vicodin、Xanax和Zoloft）评估拟定系统的性能。 4.产品使用、放置和安全性评价。评价了产品的易操作性和目标用户在整个失活过程中免受有害暴露的安全性。AIM还将评估产品分销给消费者的不同方式。 5.第二阶段原型的初步设计。重点设计第二阶段的装置原型和产品成本分析，以证明第二阶段规模扩大的拟议失活装置的可行性。

Objective: Demonstrate effectiveness of a safe, immediate, cost-effective, ecological, and user-friendly system that enables at-home deactivation and disposal of psychoactive prescription pharmaceuticals. Giner, Inc. proposes to develop a miniaturized electrolytic mixed-oxidant (MOX) system to safely destroy psychoactive pharmaceuticals in solid, liquid or patch form. The proposed system is designed to temporarily attach to a standard household faucet to eliminate need for extra equipment and to achieve size, performance and safety advantages over existing technologies. Phase I will assess overall feasibility of concept by focusing on design of MOX reactor and identifying requirements to inactivate selection of highly used pharmaceutical drugs. Phase I focus on following Specific Aims: 1. Design, Fabricate and Assemble BDD/MOX System Components. Focus on development/fabrication of compact and functional electrolytic MOX reactor unit by designing electrode structure and assembling necessary components. 2. Characterize Key Process Variables and Parameters. Process variables and parameters will be identified and optimized for sufficient electro-generation of mixed oxidants to inactivate select pharmaceutical products. 3. Demonstrate Suitable Performance of the System on Select Pharmaceuticals. Performance of proposed system will be assessed using psychoactive pharmaceutical products (Vicodin, Xanax, and Zoloft) selected for their frequency of prescription, treatment class and range of chemical structures. 4. Product Use, Placement, and Safety Evaluation. Product evaluated for ease of operation and target user safety from harmful exposure throughout entire deactivation process. Aim will also assess different ways product will be distributed to consumers. 5. Preliminary Design for Phase II Prototype. Focus on designing device prototype for Phase II and product cost analyses to demonstrate feasibility of proposed deactivation device for Phase II scale-up.